The Comparative Trial of UFT [tegafur/uracil] + TAM [tamoxifen] with CMF [cyclophosphamide + methotrexate + fluorouracil] + TAM in adjuvant therapy for breast cancer (CUBC)

Trial Profile

The Comparative Trial of UFT [tegafur/uracil] + TAM [tamoxifen] with CMF [cyclophosphamide + methotrexate + fluorouracil] + TAM in adjuvant therapy for breast cancer (CUBC)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Tegafur/uracil (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate; Tamoxifen
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 15 Sep 2009 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Aug 2009 Results have been published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top